Dendrimer enhanced irinotecan - Starpharma
Alternative Names: DEP® irinotecan; DEP® SN38; SN38-SPL9111Latest Information Update: 28 Feb 2025
At a glance
- Originator Starpharma
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 19 Dec 2024 Starpharma plans to files an IND application with the USFDA in USA for Ovarian Cancer
- 19 Dec 2024 Starpharma receives positive feedback from FDA on DEP® SN38 clinical pathway for platinum-resistant ovarian cancer
- 19 Dec 2024 Starpharma plans a phase II/III trial for Ovarian Cancer (Second-line therapy or greater)